Fertility Risk in Pediatric and Adolescent Cancers

  • Clarisa R. Gracia
  • Jill P. Ginsberg
Part of the Cancer Treatment and Research book series (CTAR, volume 138)

Recent diagnostic and therapeutic advances in pediatric oncology have led to greater survival rates in children with malignancies. However, while childhood and adolescent cancer therapies improve long-term survival, such treatments may lead to abnormal pubertal development, infertility, and gonadal failure. As more children and young adults survive childhood cancer and lead productive lives, these concerns are becoming increasingly important. Clinicians and researchers must be aware of current research in the area of fertility preservation in order to best guide patients through cancer treatment towards a healthy, fulfilled life. This chapter will review the effects of cancer treatments on reproductive potential, describe current methods of monitoring reproductive potential, and describe the fertility-sparing options available to young cancer patients of reproductive age. Specific attention will be paid to gaps in research pertinent to this topic.


Cancer Survivor Childhood Cancer Ovarian Reserve Fertility Preservation Ovarian Failure 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hewitt M, Breen N, Devesa S. Cancer prevalence and survivorship issues: analysis of 1992 National Health Interview Survey. J Natl Cancer Inst 1999;91:1480–1486.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemel A, Clegg LH, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 2004;101:3–27.CrossRefGoogle Scholar
  3. 3.
    Partridge AH, Gelber S, Peppercorn J, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22:4174–4183.PubMedCrossRefGoogle Scholar
  4. 4.
    Wenzel L, Dogan-Atles A, Habbal R, et al. Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr 2005;34:94–98.PubMedCrossRefGoogle Scholar
  5. 5.
    Burns KC, Boudreau C, Panepinto JA. Attitudes regarding fertility preservation in female adolescent cancer patients. J Pediatr Hematol Oncol 2006;28:350–354.PubMedCrossRefGoogle Scholar
  6. 6.
    Rieker PP, Fitzgerald EM, Kalish LA. Adaptive behavioral responses to potential infertility among survivors of testis cancer. J Clin Oncol 1990;8:347–355.PubMedGoogle Scholar
  7. 7.
    Green D, Galvin H, Norme B. The psycho-social impact of infertility on young male cancer survivors: a qualitative investigation. Psycho-oncology 2003;12:141–152.PubMedCrossRefGoogle Scholar
  8. 8.
    Ries LAG, Smith MA, Gurney JG, et al. Cancer Incidence and survival among children and adolescents: United States SEER Program 1975–95. National Cancer Institute, SEER Program. NIH pub. No. 99–4649. Bethesda, MD, 1999.Google Scholar
  9. 9.
    Johnson J, Canning J, Kaneko T, et al. Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature 2004;428:145–150.PubMedCrossRefGoogle Scholar
  10. 10.
    Forbasco AS, de Pol A, Vizzotto L, et al. Morphometric study of the human neonatal ovary. Anat Rec 1991;231:201–208.CrossRefGoogle Scholar
  11. 11.
    Faddy MJ, Gosden RG, Gougeon A, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992;7:1342–1346.PubMedGoogle Scholar
  12. 12.
    Chemaitilly W, Mertens AC, Mitby P. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab 2006;91:1723–1728.PubMedCrossRefGoogle Scholar
  13. 13.
    Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890–896.PubMedCrossRefGoogle Scholar
  14. 14.
    Hensley ML, Reichman BS. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit Rev Oncol Hematol 1998;28:121–128.PubMedCrossRefGoogle Scholar
  15. 15.
    Wallace WH, Blacklay A, Eiser C, et al. Developing strategies for long term follow up of survivors of childhood cancer. BMJ 2001;323:271–274.PubMedCrossRefGoogle Scholar
  16. 16.
    Thomson AB, Critchley HO, Wallace WH. Fertility and progeny. Eur J Cancer 2002;38:1634–1644.PubMedCrossRefGoogle Scholar
  17. 17.
    Damewood MD, Grochow LB. Prospects for fertility after chemotherapy or radiation of neoplastic disease. Fertil Steril 1986;45:443–459.PubMedGoogle Scholar
  18. 18.
    Meirow D, Epstein M, Lewis H, et al. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001;16:632–637.PubMedCrossRefGoogle Scholar
  19. 19.
    Warne GL, Fairley KF, Hobbs JB, et al. Cyclophosphamide-induced ovarian failure. N Engl J Med 1973;289:1159–1162.PubMedGoogle Scholar
  20. 20.
    Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977;39:1403–1409.PubMedCrossRefGoogle Scholar
  21. 21.
    Familiari G, Caggiati A, Nottola SA, et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin’s disease. Hum Reprod 1993;8:2080–2087.PubMedGoogle Scholar
  22. 22.
    Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin’s disease. I. Hormone function. JAMA 1979;242:1877–1881.PubMedCrossRefGoogle Scholar
  23. 23.
    Wallace WH, Shalet SM, Hendry JH, et al. Ovarian failure following abdominal irradiation in childhood: the radiosensitivity of the human oocyte. Br J Radiol 1989;62:995–998.PubMedCrossRefGoogle Scholar
  24. 24.
    Wallace WH, Shalet SM, Crowne EC, et al. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol 1989;1:75–79.CrossRefGoogle Scholar
  25. 25.
    Thibaud E, Ramirez M, Brauner R, et al. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr 1992;121:880–884.PubMedCrossRefGoogle Scholar
  26. 26.
    Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999;33:2–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003;18:117–121.PubMedCrossRefGoogle Scholar
  28. 28.
    Wallace WH, Thomson AB, Saran F, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005;62:738–744.PubMedGoogle Scholar
  29. 29.
    Sklar C. Growth and endocrine disturbances after bone marrow transplantation in childhood. Acta Paediatr Suppl. 1995;411:57–61; discussion 62.Google Scholar
  30. 30.
    Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. J Natl Cancer Inst Monogr 2005;34:64–68.PubMedCrossRefGoogle Scholar
  31. 31.
    Holm K, Nysom K, Brocks V, et al. Ultrasound B-mode changes in the uterus and ovaries and Doppler changes in the uterus after total body irradiation and allogeneic bone marrow transplantation in childhood. Bone Marrow Transplant 1999;23:259–263.PubMedCrossRefGoogle Scholar
  32. 32.
    Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 1999;106:1265–1272.PubMedGoogle Scholar
  33. 33.
    Larsen EC, Schmiegelow K, Rechnitzer C, et al. Radiotherapy at a young age reduces uterine volume of childhood cancer survivors. Acta Obstet Gynecol Scand 2004;83:96–102.PubMedGoogle Scholar
  34. 34.
    Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964–1988 in Ontario, Canada. Am J Epidemiol 1999;150:245–254.PubMedGoogle Scholar
  35. 35.
    Chritchley HO, Bath LE, Wallace HB. Radiation damage to the uterus–review of the effects of treatment of childhood cancer. Hum Fertil 2002;5:61–66.CrossRefGoogle Scholar
  36. 36.
    Bath LE, Anderson RA, Critchley HO, et al. Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia. Hum Reprod 2001;16:1838–1844.PubMedCrossRefGoogle Scholar
  37. 37.
    Cicognani A, Pasini A, Pession A, et al. Gonadal function and pubertal development after treatment of childhood malignancy. J Pediatr Endocrinol Metab 2003;16:321–326.PubMedGoogle Scholar
  38. 38.
    Spoudeas HA, Charmandari E, Brook CG. Hypothalamo-pituitary-adrenal axis integrity after cranial irradiation for childhood posterior fossa tumors. Med Pediatr Oncol 2003;40:224–229.PubMedCrossRefGoogle Scholar
  39. 39.
    Kanumakala S, Warne GL, Zacharin MR. Evolving hypopituitarism following cranial irradiation. J Paediatr Child Health 2003;39:232–235.PubMedGoogle Scholar
  40. 40.
    Kim S.S. Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril 2006;85:1–11.PubMedCrossRefGoogle Scholar
  41. 41.
    Anderson RA, Themmen APN, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Rep Advance Access. July 2006.Google Scholar
  42. 42.
    Chatterjee R, Mills W, Katz M, et al. Prospective study of pituitary-gonadal function to evaluate short-term effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in post-menarcheal female patients. Bone Marrrow Transplant 1994;13:511–517.Google Scholar
  43. 43.
    Wallace EM, Groome NP, Riley SC, et al. Effects of chemotherapy-induced testicular damage on inhibin, gonadotrophin and testosterone secretion: a prospective longitudinal study. J Clin Endocrinol Metab 1997;82:3111–3115.PubMedCrossRefGoogle Scholar
  44. 44.
    Kreuser E, Felsenberg D, Behles C, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin’s disease. Ann Oncol 1992;3:105–110.PubMedGoogle Scholar
  45. 45.
    Mills JL, Fears TR, Robison LL, et al. Menarche in a cohort of 188 long-term survivors of acute lymphoblastic leukemia. J Pediatr 1997;131:598–602.PubMedCrossRefGoogle Scholar
  46. 46.
    Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1996;166:788–793.Google Scholar
  47. 47.
    Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999;33:2–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol 2000;169:123–131.PubMedCrossRefGoogle Scholar
  49. 49.
    Scott RT Jr, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril 1995;63:1–11.PubMedGoogle Scholar
  50. 50.
    Muasher SJ, Oehninger S, Simonetti S, et al. The value of basal and/or stimulated serum gonadotripin levels in prediction of stimulation response and in vitro fertilization outcome. Fertil Steril 1988;50:298–307.PubMedGoogle Scholar
  51. 51.
    Toner JP, Philput CB, Jones GS, et al. Basal follicle-stimulating hormone level is a better predictor of in vitro fertilization performance than age. Fertil Steril 1991;55:784–791.PubMedGoogle Scholar
  52. 52.
    Bancsi LF, Broekmans FJ, Mol BW, et al. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil Steril 2003;79:1091–1100.PubMedCrossRefGoogle Scholar
  53. 53.
    Hendriks DJ, Mol BW, Bancsi LF, et al. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization; a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil Steril 2005;83:291–301.PubMedCrossRefGoogle Scholar
  54. 54.
    Seifer DB, Scott RT Jr, Bergh PA, et al. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertil Steril 1999;72:63–65.PubMedCrossRefGoogle Scholar
  55. 55.
    Seifer DB, Lambert-Messerlian G, Hogan JW, et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997;67:110–114.PubMedCrossRefGoogle Scholar
  56. 56.
    Seifer CB, MacLaughlin DT, Christian BP, et al. Early follicular serum mullerian-inhibing levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468–471.PubMedCrossRefGoogle Scholar
  57. 57.
    Sharara FI, McClamrock HD. The effect of aging on ovarian volume measurements in infertile women. Obstet Gynecol 1999;94:57–60.PubMedCrossRefGoogle Scholar
  58. 58.
    Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368–2374.PubMedCrossRefGoogle Scholar
  59. 59.
    Larsen EC, Muller J, Schmiegelow K, et al. Reduced ovarian function in long-term survivors of radiation and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003;33:5302–5314.Google Scholar
  60. 60.
    Larsen EC, Muller J, Rochnitzer C, et al. Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH < 10 IU/l. Hum Reprod 2003;18:417–422.PubMedCrossRefGoogle Scholar
  61. 61.
    Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer 1989;43:399–402.PubMedCrossRefGoogle Scholar
  62. 62.
    Li FP, Fine W, Jaffe N, Holmes GE, Holmes FF. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst 1979;62:1193–1197.PubMedGoogle Scholar
  63. 63.
    Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998;62:45–52.PubMedCrossRefGoogle Scholar
  64. 64.
    Green DM, Zevon MA, Lowrie G, et al. Congenital anomalies in children of patients who received chemotherapy for cancer in childhood and adolescence. N Engl J Med 1991;325:141–146.PubMedCrossRefGoogle Scholar
  65. 65.
    Nagarajan R, Robison LL. Pregnancy outcomes in survivors of childhood cancer. J Natl Cancer Inst Monogr 2005;34:72–76.PubMedCrossRefGoogle Scholar
  66. 66.
    Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005;353:64–73.PubMedCrossRefGoogle Scholar
  67. 67.
    Ginsburg ES, Yanushpolsky EH, Jackson KV. In vitro fertilization for cancer patients and survivors. Fertil Steril 2001;75:705–710.PubMedCrossRefGoogle Scholar
  68. 68.
    Kim SS. Fertility preservation in female cancer patients: current developments and future directions. Fertil Steril 2006;85:1–11.PubMedCrossRefGoogle Scholar
  69. 69.
    Ray GR, Trueblood HW, Enright LP, et al. Oophorepexy: a means of preserving ovarian function following pelvic megvoltage radiotherapy for Hodgkin’s disease. Radiology 1970;96:175–180.PubMedGoogle Scholar
  70. 70.
    Scott SM, Schlaff W. Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin’s disease. J Pediatr Adolesc Gynecol 2005;18:355–257.PubMedCrossRefGoogle Scholar
  71. 71.
    Hadar H, Loven D, Herskovitz P, et al. An evaluation of lateral and medial transposition of the ovaries out of radiation fields. Cancer 1994;74:774–779.PubMedCrossRefGoogle Scholar
  72. 72.
    Gunthert AR, Grundker C, Bottcher B, et al. Luteinizing hormone-releasing hormone (LHRH) inhibits apoptosis induced by cytotoxic agent and UV-light but not apoptosis mediated through CD95 in human ovarian and endometrial cancer cells. Anticancer Res 2004;24:1727–1732.PubMedGoogle Scholar
  73. 73.
    Ataya K, Rao LV, Lawrence E, et al. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365–372.PubMedCrossRefGoogle Scholar
  74. 74.
    Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005;34:40–43.PubMedCrossRefGoogle Scholar
  75. 75.
    Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620–1626.PubMedGoogle Scholar
  76. 76.
    Pereyra Pacheco B, Mendez Ribas JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: a preliminary report. Gynecol Oncol 2001;81:391–397.PubMedCrossRefGoogle Scholar
  77. 77.
    Tilly JL, Kolesnick RN. Sphingolipids, apoptosis, cancer treatments and the ovary. Investigating a crime against female fertility. Biochem Biophys Acta 2002;1585:135–138.PubMedGoogle Scholar
  78. 78.
    Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1 phosphate therapy. Nat Med 2000;6:1109–1114.PubMedCrossRefGoogle Scholar
  79. 79.
    Perez GI, Jurisicova A, Matikainen T, et al. A central role for ceramide in the age-related acceleration of apoptosis in the female germline. FASEB J 2005;19:860–862.PubMedGoogle Scholar
  80. 80.
    Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405–1410.PubMedCrossRefGoogle Scholar
  81. 81.
    Oktay T, Tilly J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004;364:2091–2092; author reply 2092–2093.Google Scholar
  82. 82.
    Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005;353:318–321.PubMedCrossRefGoogle Scholar
  83. 83.
    Van der Elst J. Oocyte freezing: here to stay. Hum Reprod Update 2003;9:463–470.PubMedCrossRefGoogle Scholar
  84. 84.
    Borini A, Bonu MA, Coticchio G, et al. Pregnancies and births after oocyte preservation. Fertil Steril 2004;82:601–605.PubMedCrossRefGoogle Scholar
  85. 85.
    Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987;19:1315–1321.CrossRefGoogle Scholar
  86. 86.
    Tsatsoulis A, Shalet SM, Morris ID, et al. Immunoactive inhibin as a marker of Sertoli cell function following cytotoxic damage to the human testis. Horm Res 1990;34254–34259.Google Scholar
  87. 87.
    Spitz S. The histological effects of nitrogen mustards on human tumors and tissues. Cancer 1948;1:383–398.PubMedCrossRefGoogle Scholar
  88. 88.
    Heikens J, Behrendt H, Adriaanse R, et al. Irreversible gonadal damage in male survivors of pediatric Hodgkin’s disease. Cancer 1996;78:2020–2024.PubMedCrossRefGoogle Scholar
  89. 89.
    Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol 1996;27:74–78.PubMedCrossRefGoogle Scholar
  90. 90.
    Papadakis V, Vlachopapadopoulou E, Van Syckle K, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol 1999;32:366–372.PubMedCrossRefGoogle Scholar
  91. 91.
    Hansen PV, Hansen SW. Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy. Eur Urol 1993;23:153–156.PubMedGoogle Scholar
  92. 92.
    Sherins RJ, Olweny CL, Ziegler JL. Gynaecomastia and gonadal dysfunction in adolescent boys treated with combination chemotherapy for Hodgkins disease. N Engl J Med 1978;299:12–16.PubMedCrossRefGoogle Scholar
  93. 93.
    Aubier F, Flamamant F, Brauner R, et al. Male gonadal function after chemotherapy for solid tumors in childhood. J Clin Oncol 1989;7:304–309.PubMedGoogle Scholar
  94. 94.
    Ben Arush MW, Solt I, Lightman A, et al. Male gonadal function in survivors of childhood Hodgkin and non-Hodgkin lymphoma. Pediatr Hematol Oncol 2000;17:239–245.PubMedCrossRefGoogle Scholar
  95. 95.
    Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998;27:927–943.PubMedCrossRefGoogle Scholar
  96. 96.
    Buchanan JD, Fairley KF, Barrier JU. Return of spermatogenesis after stopping cyclophosphamide therapy. Lancet 1975;2:156–157.PubMedCrossRefGoogle Scholar
  97. 97.
    Watson AR, Rance CP, Bain J. Long-term effects of cyclophosphamide on testicular function. Br Med J 1985;291:1457–1460.CrossRefGoogle Scholar
  98. 98.
    da Cunha MF, Meistrich ML, Fuller LM. Recovery of spermatogenesis after treatment for Hodgkin’s disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2:571–577.PubMedGoogle Scholar
  99. 99.
    Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update 2001;7:363–369.PubMedCrossRefGoogle Scholar
  100. 100.
    Pryzant RM, Meistrich ML, Wilson G. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin’s lymphomas. J Clin Oncol 1993;11:239–247.PubMedGoogle Scholar
  101. 101.
    Shalet SM, Tsatsoulis A, Whitehead E, et al. Vulnerability of the human Leydig cell to radiation damage is dependent upon age. J Endocrinol 1989;120:161–165.PubMedCrossRefGoogle Scholar
  102. 102.
    Chatterjee R, Jaines GA, Perera DM, et al. Testicular and sperm DNA damage after treatment with fludarabine for chronic lymptocytic leukaemia. Hum Reprod 2000;15:762–766.PubMedCrossRefGoogle Scholar
  103. 103.
    Thomson AB, Campbell AJ, Irvine DC, et al. Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case–control study. Lancet 2002;360:361–367.PubMedCrossRefGoogle Scholar
  104. 104.
    Meistrich ML, Byrne J. Genetic disease if offspring of long-term survivors of childhood and adolescent cancer treated with potentially mutagenic therapies. Am J Hum Genet 2002;70:1069–1071.PubMedCrossRefGoogle Scholar
  105. 105.
    Ash P. The influence of radiation on fertility in man. Br J Radiol 1980;53:271–278.PubMedCrossRefGoogle Scholar
  106. 106.
    Sklar CA, Robison LL, Nesbit ME, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol 1990;8:1981–1987.PubMedGoogle Scholar
  107. 107.
    Castillo LA, Craft AW, Kernahan J, Evans R.G. and Aynsley-Green A. Gonadal function after 12-Gy testicular irradiation in childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1990;18:185–189.PubMedCrossRefGoogle Scholar
  108. 108.
    Schmiegelow ML, Sommer P, Carlsen E, et al. Penile vibratory stimulation and electroejaculation before anticancer therapy in two pubertal boys. J Pediatr Hematol Oncol 1998;20:429–430.PubMedCrossRefGoogle Scholar
  109. 109.
    Shover LR, Brey K, Lichtin A, et al. Oncologists’ attitudes and practices regarding banking sperm before cancer treatment. J Clin Oncol 2002;20:1890–1897.CrossRefGoogle Scholar
  110. 110.
    Magelssen H, et al. Twenty years experience with semen cryopreservation in testicular cancer patients: who needs it? Eur Urol 2005;48:779–785.PubMedCrossRefGoogle Scholar
  111. 111.
    Johnson DH, Linde R, Hainsworth JD, et al. Effect of luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood 1985;65:832–836.PubMedGoogle Scholar
  112. 112.
    Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 1987;19:159–162.PubMedCrossRefGoogle Scholar
  113. 113.
    Brinster LR, Avarbock MR. Germline transmission of donor haplotype following spermatogonial transplantation. Proc Natl Acad Sci 1994;91:11303–11307.PubMedCrossRefGoogle Scholar
  114. 114.
    Zhang Z, Renfree MB, Short RV. Successful intra- and inter-specific male germ cell transplantation in the rat. Biol Reprod 2003;68:961–963.PubMedCrossRefGoogle Scholar
  115. 115.
    Nisker J, Baylis F, McLeod C. Choice in fertility preservation in girls and adolescent women with cancer. Cancer 2006;107:1686–1689.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Clarisa R. Gracia
  • Jill P. Ginsberg

There are no affiliations available

Personalised recommendations